Opiant Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was USD 0.174 million compared to USD 16.34 million a year ago. Net loss was USD 9.92 million compared to net income of USD 3.42 million a year ago. Basic loss per share from continuing operations was USD 1,930 compared to basic earnings per share from continuing operations of USD 770 a year ago. Diluted loss per share from continuing operations was USD 1,930 compared to diluted earnings per share from continuing operations of USD 560 a year ago.
For the nine months, revenue was USD 8.54 million compared to USD 33.99 million a year ago. Net loss was USD 33.84 million compared to net income of USD 2.26 million a year ago. Basic loss per share from continuing operations was USD 6,660 compared to basic earnings per share from continuing operations of USD 520 a year ago. Diluted loss per share from continuing operations was USD 6,660 compared to diluted earnings per share from continuing operations of USD 410 a year ago.